Objectives: To evaluate a community-based screening programme for detecting neonata/liver disease by the quantitation of conjugated bilirubin in blood.
Conclusions:
Conjugated bilirubin in plasma measured at 6-1 0 days is a reliable marker for neonatal liver disease, and a population screening programme based on this method has the potential to improve the survival and quality of life of infants born with liver disease. However, testing as part of the neonatal screening programme will prove practical only iF the method can be adapted to use dried blood spots. N eona tal liver disease affects 0.02-0.04% of all newborn babies.v' The commonest single cause is extrahepatic biliary atresia (EHBA), affecting 1 in 14,000 live births.' Other causes include congenital infections (of many different aetiologies), alpha-I-antitrypsin deficiency, choledocal cysts and inborn errors of metabolism." Neonatal liver disease is rarely diagnosed before the first health surveillance check at six weeks of age since jaundice, the first clinical sign, is common, affecting 2.4-15% of babies over two weeks old. ' Early diagnosis is desirable, because surgical correction of EHBA (Kasai portoenterostomy) is considerably more successful under 60 days of age.?" although surgical expertise is also a factor.":" Early intervention may also benefit other specific conditions, e.g. NTBC treatment in tyrosinaemia Type 1.II Prompt nutritional management can minimise the protein-energy malnutrition and growth failure commonly associated with liver disease." Finally, vitamin K deficiency caused by undiagnosed liver disease is a common cause of severe bleeding in infants."
In 1993 the Yellow Alert campaign attempted early detection of neonatal liver disease by recommending that jaundiced babies over 14 days old should be tested for urinary bilirubin and/or conjugated bilirubin in blood." However, the large number of children involved (up to 15% of babies) and difficulties with the quality control of assays for conjugated bilirubin meant that this recommendation was never widely implemented. 14 Abnormal stool colour has also been suggested as a means of detecting cholestatic liver disease." Current guidance to aid early detection of liver disease emphasises the importance of urine and stool colour. 16 www.jmedscreen.com An alternative approach would be to undertake universal screening using the routine blood specimens (usually dried blood spots) collected at approximately 6 days for phenylketonuria (PKU) and congenital hypothyroidism (CHT) screening. However, a screening test applicable to dried blood spots in large numbers is not yet available. Tandem mass spectrometry has been used to measure specific bile acids, 17 but fails adequately to discriminate between normal children and those with liver disease.
In some areas of the UK, including until recently the Birmingham Health District, liquid capillary blood is collected from neonates. In a previous pilot study based in Birmingham, 1157 liquid blood samples were tested for conjugated bilirubin using surplus plasma from routine neonatal screening specimens." Using cut-off points derived from the pilot study, a prospective population-based screening programme was undertaken, the results of which are now reported.
PATIENTS AND METHODS

Subjects and specimens
All babies under 28 days old having routine neonatal screening for PKU and CHT in the Birmingham Health District between 1 August 1995 and 31 July 1997 were eligible for inclusion in the study. A distinction was made between subjects tested in the community (i.e. residents of the Birmingham Health District) and babies hospitalised at the time of screening. The latter subjects were a mixture of Birmingham residents and outside referrals to the Birmingham Children's Hospital (BCH), a tertiary referral centre for liver disease and other conditions. As some of these subjects may have had pre-existing liver dysfunction, they were analysed separately.
The study was approved by the local Health District ethical committees. Before collecting specimens, midwives gave parents an information leaflet asking for their participation in the study, and babies were excluded from the study if requested. Personal demographics recorded for the routine screening programme, including age at specimen collection, gestational age, sex and ethnic origin, were anonymised but linked to the bilirubin results. All specimens were collected in opaque tubes, transported to the laboratory protected from light and stored in the dark at 4°C in the laboratory. Spare plasma from the heparinised liquid blood specimens was analysed only after completion of routine screening. No additional blood was collected, and routine testing took precedence. The time between collection and receipt in the laboratory (transit time), and receipt and analysis (specimen age) were recorded. Where repeat specimens had been taken as part of the routine screens, the first specimen giving a valid result was used. Grossly haemolysed samples (as examined by eye) were excluded, because of possible assay interference. 19
Laboratory analysis
The two main fractions of bilirubin, conjugated (BC) and unconjugated (BU), were measured in plasma specimens by dry slide chemistry using a Johnson & Johnson Yitros (Kodak Ektachem, Rochester, NY, USA) 700 analyser, requiring 50 l!l plasma for both tests. The method is based on measurement of the reflection density at two wavelengths; different molar absorptivities enable the concentration of both fractions to be separately determined using a single slide. The between-batch analytical coefficients of variation were 2.7% for BU at 186 urnol/I and 4.2% for BC at 96 umol/l (n=20 in each case). Using data from our pilot study, abnormal results (i.e. values above the 97.5th percentile) were defined as BC more than 18l!molll and the conjugated fraction BC% (i.e. 100xBC/[BU+BC]. rounded to the nearest integer) more than 20%.
Follow-up procedures
All subjects with a BC>18 umol/I and BC%>20% were followed-up. Community-based babies received a home visit by a Clinical Nurse Specialist who obtained a second heelprick sample for repeat bilirubin fractions and liver function tests (aspartate aminotransferase, AST; alanine aminotransferase, ALT; alkaline phosphatase, ALP; gamma-glutamyl transferase, yGT and assessed the baby clinically. If the results of this second blood test were abnormal, the baby was referred to the Liver Unit at BCH for further investigations. The baby's general practitioner and midwife were informed of all abnormal results and subsequent action taken. Hospitalised babies with abnormal results also received a second test, and if their existing condition or treatment did not explain the abnormal result, they were also investigated by the Liver Unit.
To identify false-negatives (children developing liver disease in the first year of life, but whose screening result was normal), all neonatologists/paediatricians and clinical chemistry laboratories within the Birmingham Health District were contacted at both the start and end of the project with an explicit request for information on all patients with liver disease. As the Liver Unit at BCH is the www.jmedscreen.com 113 nearest tertiary referral centre and provides a national service, it was likely that all such patients would have been referred there, or that the unit would have become aware of cases. Similarly, the Clinical Chemistry Department provides a tertiary laboratory diagnostic service for such cases, i.e. missed cases requiring specialist tests would have been referred for investigation.
Data analysis
Summary statistics (mean, median, interquartile and 95 percentile ranges) were derived for total bilirubin, conjugated bilirubin and conjugated fraction. The sensitivity, specificity and positive predictive value (PPY) of the test, with 95% confidence intervals, were also derived.
RESULTS
Community-based subjects
Subject and specimen characteristics Screening specimens from 27,654 community-based babies were received during the two-year study period. Of these, 4219 specimens (15.3%) were untestable, mostly because of gross haemolysis (8.6%) or insufficient plasma remaining after routine screening (5.8%). A further 221 were excluded because the baby was over 27 days old. Table 1 shows subject and specimen characteristics of the remaining 23,214 samples. The distributions of sex and ethnic group were similar to those of the pilot study. 1M However, the median gestational age was higher (40 weeks, compared with 39 weeks) than in the pilot study, and the median age at collection, specimen age and transit times were each one day greater than in the pilot. Table 2 shows the distribution of the test results. The 97. 5th percentile value for total bilirubin (TB; 265 umol/I) was similar to that found in the pilot study (285 umol/I) but the values for BC and BC% were higher (BC 21 umol/l vs 18l!mol/l; BC% 45% vs 20%).
Bilirubin concentrations
In 2952 (12.7%) specimens, BC was below the limit of detection «1 umol/I), In 878 (3.8%) specimens, BC levels exceeded the cut-off point of 18l!mol/1. The cut-off point for BC% (i.e. 20%) was exceeded in 3748 (16.1 %) specimens. However, only 107 specimens (0.46% of those screened) exceeded both cut-off points. 
Follow-up of elevated results
Of the 107 babies with a positive first test, 12 (11 %) remained abnormal on repeat testing and were examined at the BCH Liver Unit (Table 3 ). Of these, 11 had clinical liver disease, including six with neonatal hepatitis and two with EHBA. These latter cases underwent Kasai operations: one at five weeks of age was unsuccessful and the child died awaiting liver transplant; the other, carried out at seven weeks, was successful. The one false-positive case was an a-I-antitrypsin deficiency carrier.
No clinical cases of liver disease were notified to us, after specific enquiries to both paediatricians and laboratories, from among the 23,107 babies having a normal test. However, six cases of liver disease (including one EHBA, who had an unsuccessful Kasai operation at seven weeks) were found amongst the 2389 children whose specimens could not be tested because of gross haemolysis or insufficient sample (Table 4 ). In this group there were four babies with neonatal hepatitis (one associated with cytomegalovirus, the others idiopathic). While these cases might be regarded as false-negatives, in a routine screening programme a repeat specimen would normally have been requested, which might well have led to their detection.
From amongst the 221 specimens excluded because the baby was over 27 days old, one case of Byler's disease was detected in an otherwise asymptomatic baby (first test at 62 days, BC=36 urnol/l. BC%=62; second test at 69 days, BC=78 urnol/l, BC%=87). It cannot be assumed, however, that this case would have been detected had the test been carried out earlier.
The sensitivity of the initial test was 100% (95%CI 76.2-100), the specificity was 99.59% (95%CI 99.5-99.67 ) and the PPY 10.3% (95%CI 4.5-16.0). By raising the cut-off point for BC to 19 umol/l while keeping the BC% cut-off at 20%, the specificity could have increased to 99.67% and the PPY to 12.5% without reducing the sensitivity.
Hospitalised subjects
A total of 2425 samples were collected from babies who were hospitalised at the time of their test. Of the 2161 testable samples from babies under 28 days, 81 (3.7%) were positive on the first test and 43 (2.0%) on the second test. In most of these cases, the liver dysfunction was secondary to some other condition: in 16 (37%) cardiac abnormalities, in 13 (30%) parenteral nutrition, and in eight (19%) other causes (sepsis, prematurity, rhesus incompatibility). However, six children (14%) had primary liver diseasesthese included hypopituitarism, hepatic haemangioma, two cases of neonatal hepatitis and two metabolic diseases (haemochromatosis and phosphoenol pyruvate carboxykinase deficiency). Five cases were already under investigation for liver abnormalities at the time of the screening test, but the case of hypopituitarism was detected as a result of the screening programme. This child, initially admitted at 12 hours for hypoglycaemia and hypothermia, had been sent home well (although still jaundiced) at seven days and was followed-up in the community. This case is not included in the community analysis since the baby was in hospital at the time of the first test.
One inpatient with a normal test result at six days (BC= 2711molll, BC%= 11 %) was later found to have had primary liver disease (neonatal hepatitis diagnosed at nine weeks) and was therefore a false-negative. 
DISCUSSION
Population screening for neonatal liver disease offers a means of improving the referral age of infants with cholestatic liver disease and therefore their prognosis. Our study demonstrates that conjugated bilirubin is an effective marker for such a programme in the community. Hospitalised babies would require a modification of the follow-up protocol. though it should be noted that inpatients in a paediatric referral centre such as BCH are a specialised group.
The dry chemistry methodology is well established and is used for analysis of bilirubin fractions in clinical chemistry laboratories. The equipment requires little maintenance and minimal training to operate; processing approximately 30 specimens/hour, an annual throughput of 60,000 specimens is logistically feasible with one analyser.
Because the specimens used had been collected for PKU and CHT screening, the additional costs of this study were those of measuring conjugated bilirubin in the specimens, and laboratory and clinical follow-up. The analytical marginal cost of the test was approximately £1 per specimen.
A major problem with this study was the high rate of haernolysis, and it is acknowledged that a repeat rate of 15% is unacceptably high. However, it is probable that as an established screening programme the rate could be lowered. In the first three months of the study (during a hot summer) 22% of specimens were haemolysed, but this fell to 7% after midwives were given coolbags for specimen transport. Haemolysis rates were lower in specimens reaching the laboratory within a day of collection and analysed within a week of receipt (data not shown), suggesting that haemolysis might be reduced to 3-4% by prompt transport and earlier testing. Additionally, 6% of specimens failed due to insufficient quantity; this could be prevented by training the midwives. Assuming an overall repeat rate of 4% at a collection cost of £11.29 per sample." the cost of the test would increase by a further 45 pence per test.
For Birmingham (approximately 14,000 births per year) the annual cost of screening by this method would be £20,300. While this does not include the capital cost of the chemistry analyser, or of laboratory and clinical follow-up, it compares favourably with the expected savings. In a population of this size, one case of EHBA would be expected each year. If one liver transplant were prevented or delayed each year (costing £45,000 and thereafter £4500 per annurrr" in comparison with £12,000, the cost of a Kasai operation), the screening programme would be costeffective. However, a full economic evaluation would be needed were this to be taken further.
The cut-off points suggested by the pilot study" were adequate for the detection of cases. In the community-based series the specificity of 99.6% might have been raised to 99.7% by raising the cut-off points for BC to >19 umol/I, leaving BC% unchanged at >20%. As no false-negatives were found, the sensitivity was 100%. Although we cannot be certain that missed cases were not notified to us, we feel this is unlikely because of the process used to identify them and the high awareness of the study amongst paediatricians and clinical chemists in Birmingham. However, one falsenegative was found in the hospitalised series, giving a sensitivity in the combined population of 94.4% (17118).
These performance data do not take into account the cases not detected because the babies were not tested (i.e. haemolysed or insufficient specimens). It is impossible to know whether, if repeat specimens had been collected on these cases, the diagnoses would have been made. Further www.jmedscreen.com 115 assessment of screening performance would be required as part of an established programme.
The higher values for the 97.5th percentiles for BC and BC% in this study compared with those of the pilot (BC 21 umol/l vs 18 urnol/l, BC% 45% vs 20%) are probably explained by differences in the degree of haemolysis. Haemolysis rates were high, as routine screening had to be completed before specimens were released for the project, and there was a median delay of nine days between collection and analysis (vs eight days in the pilot). The exclusion of slightly to moderately haemolysed specimens from the pilot (but not from the current study) is likely to be the main explanation for the increase in the BC%.
Before embarking on population screening, the programme must be assessed according to the Wilson and Jungner criteria." a widely accepted guide to the validity of a screening programme. Most of these criteria are fulfilled for EHBA, Alagille criteria syndrome and hypopituitarism, including the seriousness of the disorder, the need for an acceptable treatment and available facilities for diagnosis and treatment. Alagille syndrome is a multi-system disorder with significant cardiac and renal disease; an early diagnosis would allow management of these conditions as well as reducing the longterm effects of cholestasis such as rickets and malnutrition. These disorders have an early symptomatic stage at which treatment improves prognosis; detection of these conditions by screening would be advantageous. The situation is less clear for neonatal hepatitis and a-I-antitrypsin deficiency. However, there are some potential advantages from early detection by screening.
Early diagnosis for neonatal hepatitis (of whatever cause) enables prevention of malnutrition with adequate nutrition, and treatment of cholestasis with consequent reduction/prevention in fat-soluble vitamin defidency leading to coagulopathy and metabolic bone diseases. Genetic counselling is an added benefit for some. a-I-Antitrypsin deficiency is more difficult because not all cases lead to liver disease and prognosis is variable. Nevertheless, early diagnosis enables the family to obtain genetic counselling and information about potential development of emphysema or liver disease in carriers, with advice about smoking and alcohol intake later in life. For children with severe a-I-antitrypsin deficiency, the benefits are as described for other cases of neonatal hepatitis.
The main problem to date in screening for liver disease has been the availability of a suitable screening test with good sensitivity and specificity." One reason why conjugated bilirubin screening has not previously been studied is probably that most programmes use dried blood spots. At the time of this study, liquid blood was collected from around 18% of UK neonates, but dried blood spot collection is becoming more common because of the trend for additional screening for metabolic disorders. Since this project was completed, there has been a switch to the collection of dried blood spots in Birmingham. For this reason, further progress toward a screening programme will require adaptation to dried blood spots.
To date, efforts by us to measure conjugated bilirubin in dried blood spots using tandem mass spectrometry have not been successful and further developments would be necessary before screening using conjugated bilirubin could be established.
